Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07052422 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Name: VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT — clinical trial record (NCT07052422)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorNanfang Hospital, Southern Medical University

Started2025-07-15

View on ClinicalTrials.gov ↗

Nanfang Hospital, Southern Medical University

182 trials monitored

See 2 trials at risk

The purpose of this study is to compare the efficacy and safety of venetoclax+decitabine+busulfan+fludarabine (VEN+DAC+Bu2Flu4) regimen with busulfan+fludarabine (Bu2Flu5) regimen in older patients with myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Trial Details

NCT Number	NCT07052422
Lead Sponsor	Nanfang Hospital, Southern Medical University
Conditions	Older Patients, Myeloid Malignancies, Conditioning, Hematopoietic Stem Cell Transplantation (HSCT)
Enrollment	160 participants
Start Date	2025-07-15
Primary Completion	2027-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-07-04